CompletedNot Applicable

Evaluation of Respiratory Function During Self-induced Cognitive Trance

France9 participantsStarted 2023-05-26

Plain-language summary

The goal of this Prospective, monocentric, non-randomized, open-label study aimed at evaluating the variation of FEV1 during a state of self-induced cognitive trance participant population: Person with expertise in the practice of TCAI can be inclued. (at least 6 months, in order to be able to control the depth of the trance and to have a motor control allowing the realization of a spirometry) The main question: Study the significant variation of FEV1 before, during, or after the state of self-induced cognitive trance

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Person over 18 years old * Person with expertise in the practice of TCAI. (at least 6 months, in order to be able to control the depth of the trance and to have a motor control allowing the realization of a spirometry) * Person affiliated with social security or beneficiary of such a scheme. * Person having given, in writing, their free and informed consent to participate in the study Exclusion Criteria: * Person deprived of liberty by judicial or administrative decision, person subject to a measure of legal protection. * Exclusion period for other studies * Person likely, according to the investigator's assessment, not to be cooperative or respectful of the obligations inherent in participation in the study * Person with a psychiatric, neurological or cardiovascular disease. * Person with a chronic respiratory disease, for example: asthma, COPD, interstitial lung disease, bronchial dilation, cystic fibrosis, * Person with a history of exercise-induced bronchospasm. * Person taking inhaled treatments (corticotherapy, bronchodilators, anticholinergics) * Pregnant woman (declarative).

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

FEV during a state of self-induced cognitive trance

Timeframe: 3 month

Trial details

NCT IDNCT06121960

SponsorCentre Hospitalier Metropole Savoie

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-01-01

View on ClinicalTrials.gov More Respiratory Function trials